

The Top Ways to Trade the Coronavirus Outbreak

The coronavirus has now gotten way out of control.

Globally, 78,442 people have been infected and more than 2,456 have already died. And, according to Dr. Nancy Messonnier, director of the National Center for Immunization and Respiratory Diseases, "This new virus represents a tremendous public health threat."

The World Health Organization (WHO) is warning of a shrinking window of opportunity to stop the spread of the deadly virus, as it spreads to 30 countries. "The window of opportunity is still there. But our window of opportunity is narrowing," said WHO Director-General Tedros Adhanom Ghebreyesus. "We need to act quickly before it closes completely."

However, there's evidence the virus has become unstoppable.

According to CNN, Italy had more than 130 confirmed cases, which makes the region the hardest hit in Europe. It's gotten so bad that towns and areas impacted by the virus in Italy have now been placed in lockdown.

Japan has 738 cases with three deaths. South Korea has 602 cases with five deaths. Singapore now has 89 deaths. Hong Kong has 74 cases and two deaths. There were another two deaths in Iran, with 13 new cases confirmed. In South Korea, the number of cases doubled in 24 hours, reaching 204. Australia confirmed six new cases.

As the issue grows worse, some of the top stocks to consider are:

Alpha Pro Tech (APT), which manufactures masks and protective clothing, has seen its share price rocket from \$3.60 to \$6.40 in recent days.



Inovio Pharmaceuticals (INO) is also still gaining traction after receiving a grant of up to \$9 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for the coronavirus. Maxim Group analysts reiterated a buy rating on the stock with a near-term price target of \$6.



Johnson & Johnson (JNJ) is an opportunity, as well. Racing against the clock, JNJ and the U.S. government recently expanded their partnership with regards to the virus. Reportedly, the U.S. will support the company's attempt to develop antiviral drugs that can help people that already contracted the virus.



Even **Gilead Sciences (GILD)** is offering opportunity. The company already started testing its antiviral remdesivir in patients with success. Preliminary results from GILD's clinical trials are expected in the next three weeks, says the World Health Organization.

